2021
American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease
Fix OK, Blumberg EA, Chang K, Chu J, Chung RT, Goacher EK, Hameed B, Kaul DR, Kulik LM, Kwok RM, McGuire BM, Mulligan DC, Price JC, Reau NS, Reddy KR, Reynolds A, Rosen HR, Russo MW, Schilsky ML, Verna EC, Ward JW, Fontana RJ, Group F. American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease. Hepatology 2021, 74: 1049-1064. PMID: 33577086, PMCID: PMC8014184, DOI: 10.1002/hep.31751.Peer-Reviewed Original ResearchConceptsMRNA COVID-19 vaccineCOVID-19 vaccineChronic liver diseaseLiver diseaseModerna mRNA COVID-19 vaccinesCoronavirus disease 2019 (COVID-19) infectionExpert panel consensus statementPrevious drug reactionsAdvanced liver diseaseLiver transplant recipientsAvailable COVID-19 vaccinesDisease 2019 infectionSevere hypersensitivity reactionsLocal site reactionsCare of patientsClinical trial participantsHealth care providersLT recipientsTransplant recipientsAdult patientsImmunosuppressed patientsSystemic reactionsHypersensitivity reactionsSite reactionsVaccine efficacy
2020
The Impact of COVID‐19 on Organ Donation, Procurement, and Liver Transplantation in the United States
Merola J, Schilsky ML, Mulligan DC. The Impact of COVID‐19 on Organ Donation, Procurement, and Liver Transplantation in the United States. Hepatology Communications 2020, 5: 5-11. PMID: 33043228, PMCID: PMC7537114, DOI: 10.1002/hep4.1620.Peer-Reviewed Original ResearchLiver transplantationOrgan recoveryOrgan transplantationSevere acute respiratory syndrome coronavirus type 2End-stage liver diseaseOrgan donationExpected excellent outcomesLiver transplant recipientsCoronavirus disease 2019 (COVID-19) pandemicCoronavirus type 2Life-saving procedureCoronavirus disease 2019Disease 2019 pandemicOrgan procurement organizationsHealth care systemTransplant recipientsOrgan failureLiver diseaseDonor evaluationExcellent outcomesDisease 2019New practice paradigmHospital resourcesType 2Particular patientClinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID‐19 Pandemic: AASLD Expert Panel Consensus Statement
Fix OK, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, Pratt DS, Russo MW, Schilsky ML, Verna EC, Loomba R, Cohen DE, Bezerra JA, Reddy KR, Chung RT. Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID‐19 Pandemic: AASLD Expert Panel Consensus Statement. Hepatology 2020, 72: 287-304. PMID: 32298473, PMCID: PMC7262242, DOI: 10.1002/hep.31281.Peer-Reviewed Original ResearchMeSH KeywordsBetacoronavirusComorbidityConsensusCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentDrug InteractionsGastroenterologyHumansImmunosuppression TherapyInternship and ResidencyLiver DiseasesLiver TransplantationOccupational HealthPandemicsPatient SafetyPneumonia, ViralPractice Guidelines as TopicSARS-CoV-2Tissue DonorsConceptsLiver transplant providersTransplant providersLiver diseaseHealthcare providersCOVID-19 pandemicExpert panel consensus statementLiver transplant recipientsCare of patientsCoronavirus disease 2019SARS-CoV-2 virusCOVID-19Transplant recipientsIll patientsLiver patientsClinical recommendationsConsensus statementDisease 2019PatientsPatient careDiseaseCareHepatologistsCOVID-19 pandemic impactBest practice advicePractice advice
2017
Predictors of Waitlist Mortality in Portopulmonary Hypertension
DuBrock HM, Goldberg DS, Sussman NL, Bartolome SD, Kadry Z, Salgia RJ, Mulligan DC, Kremers WK, Kawut SM, Krowka MJ, Channick RN. Predictors of Waitlist Mortality in Portopulmonary Hypertension. Transplantation 2017, 101: 1609-1615. PMID: 28207639, PMCID: PMC5481480, DOI: 10.1097/tp.0000000000001666.Peer-Reviewed Original ResearchMeSH KeywordsArterial PressureCause of DeathChi-Square DistributionDatabases, FactualDecision Support TechniquesFemaleHumansHypertension, PortalHypertension, PulmonaryKaplan-Meier EstimateLiver DiseasesLiver TransplantationMaleMiddle AgedMultivariate AnalysisPortal PressurePredictive Value of TestsProportional Hazards ModelsPulmonary ArteryPulmonary CirculationRetrospective StudiesRisk AssessmentRisk FactorsSeverity of Illness IndexTime FactorsTissue and Organ ProcurementTreatment OutcomeVascular ResistanceWaiting ListsConceptsPortopulmonary hypertensionWaitlist mortalityMELD exceptionsLiver diseaseException scoreEnd-Stage Liver Disease (MELD) exception pointsSignificant predictorsCox proportional hazards modelMELD exception scoreWaitlist mortality riskRetrospective cohort studyPulmonary arterial pressureTransplantation Network databaseSignificant univariate predictorsOnly significant univariate predictorsProportional hazards modelMELD scorePosttransplant mortalityPulmonary hypertensionCohort studyArterial pressureUnivariate predictorsC-statisticMortality riskHazards modelInequity in organ allocation for patients awaiting liver transplantation: Rationale for uncapping the model for end-stage liver disease
Nadim MK, DiNorcia J, Ji L, Groshen S, Levitsky J, Sung RS, Kim WR, Andreoni K, Mulligan D, Genyk YS. Inequity in organ allocation for patients awaiting liver transplantation: Rationale for uncapping the model for end-stage liver disease. Journal Of Hepatology 2017, 67: 517-525. PMID: 28483678, PMCID: PMC7735955, DOI: 10.1016/j.jhep.2017.04.022.Peer-Reviewed Original ResearchConceptsEnd-stage liver diseaseLiver transplantMELD scoreLiver diseaseSick patientsLiver transplantationOrgan allocationEquitable organ distributionGreater MELD scoresPost-transplant outcomesOrgan Sharing dataPost-transplant survivalUnderwent liver transplantObjective scoring systemWaitlist registrationWaitlist mortalityHazard ratioSurvival benefitWaitlist candidatesUnited NetworkPatientsTransplantScoring systemMELDOrgan distributionLiver allocation and distribution
Deshpande R, Hirose R, Mulligan D. Liver allocation and distribution. Current Opinion In Organ Transplantation 2017, 22: 162-168. PMID: 28212159, DOI: 10.1097/mot.0000000000000397.Peer-Reviewed Original ResearchConceptsTransplant CommitteeTransplant centersEnd-Stage Liver Disease (MELD) pointsLiver allograft allocationDeceased donor liversLife-saving organsLiver allocation policyAllograft allocationLiver transplantLiver transplantationLiver diseaseDonor liversUnited NetworkDonor organsLiver distributionAdvanced stageLiver allocationOrgan distributionPatient accessTransplantationGeographic disparitiesLiverDisease pointHealthcare systemPatients
2016
The impact of broader regional sharing of livers: 2‐year results of “Share 35”
Edwards EB, Harper AM, Hirose R, Mulligan DC. The impact of broader regional sharing of livers: 2‐year results of “Share 35”. Liver Transplantation 2016, 22: 399-409. PMID: 26890858, DOI: 10.1002/lt.24418.Peer-Reviewed Original ResearchConceptsWaiting list mortalityLiver transplantLiver diseaseEnd-stage liver disease candidatesEnd-stage liver diseasePosttransplant survival outcomesChronic liver diseaseCold ischemia timeShare 35 policyRegional sharingBroader regional sharingPost-policy periodPosttransplant graftUrgent groupIschemia timePatient survivalSurvival outcomesMedian MELDMortality rateSickest candidatesOrgan procurementTransplantation NetworkTransplantAge groupsUrgent patients
2015
Non‐alcoholic fatty liver disease following liver transplantation: a clinical review
Merola J, Liapakis A, Mulligan DC, Yoo PS. Non‐alcoholic fatty liver disease following liver transplantation: a clinical review. Clinical Transplantation 2015, 29: 728-737. PMID: 26147308, DOI: 10.1111/ctr.12585.Peer-Reviewed Original ResearchConceptsNon-alcoholic steatohepatitisLiver transplantationRisk factorsNon-alcoholic fatty liver diseasePost-transplant metabolic syndromePost-transplant settingCardiovascular risk factorsPost-transplantation outcomesSignificant survival benefitFatty liver diseaseCause of deathCardiovascular mortalitySurvival benefitMetabolic syndromeLiver diseaseClinical reviewPatient populationSurgical approachTreatment approachesTransplantationRecent evidenceIndicationsSteatohepatitisTransplantSyndrome
2013
Successful Abdominal Organ Donation after Brain Death in a Patient with a Biventricular Assist Device: Extending Extended Criteria
Carpenter S, Steidley D, Douglas D, Reddy K, Mulligan D, Lanza L, Moss A. Successful Abdominal Organ Donation after Brain Death in a Patient with a Biventricular Assist Device: Extending Extended Criteria. Open Journal Of Organ Transplant Surgery 2013, 2013: 32-35. DOI: 10.4236/ojots.2013.32006.Peer-Reviewed Original ResearchEnd-organ functionMechanical circulatory supportBiventricular assist deviceBrain deathAssist deviceAdequate end-organ functionOngoing mechanical circulatory supportProfound cardiogenic shock refractoryIntra-aortic balloon pumpLeft ventricular assist deviceMELD exception scoreStatus 1 patientsExcellent graft functionCardiogenic shock refractoryAcute myocardial infarctionPolycystic liver diseaseVentricular assist deviceGraft functionBalloon pumpHeparin dripShock refractoryBypass graftLiver diseaseCirculatory supportCerebellar hemorrhage
2009
Sclerosing peritonitis and mortality after liver transplantation
Mekeel K, Moss A, Reddy KS, Douglas D, Mulligan D. Sclerosing peritonitis and mortality after liver transplantation. Liver Transplantation 2009, 15: 435-439. PMID: 19326414, DOI: 10.1002/lt.21702.Peer-Reviewed Original ResearchMeSH KeywordsAbdominal PainAdultAscitesBacterial InfectionsCholestasisEndoscopy, Digestive SystemFatal OutcomeHumansIntestinal ObstructionLiver DiseasesLiver TransplantationMaleMalnutritionMiddle AgedParacentesisPeritonitisReoperationRisk FactorsSclerosisTomography, X-Ray ComputedTreatment OutcomeVascular DiseasesConceptsLiver transplantationBowel obstructionRefractory ascitesBacterial peritonitisEnd-stage liver diseasePartial small bowel obstructionMassive refractory ascitesSmall bowel obstructionEpisodes of peritonitisSpontaneous bacterial peritonitisTime of transplantationAbdominal painBiliary obstructionLiver diseasePeritoneal dialysisInferior venaPeritoneal surfaceFibrous peelPeritonitisPatientsTransplantationAscitesObstructionComplicationsEpisodes
2008
Living donor liver transplantation in polycystic liver disease
Mekeel KL, Moss AA, Reddy KS, Douglas DD, Vargas HE, Carey EJ, Byrne TJ, Harrison ME, Rakela J, Mulligan DC. Living donor liver transplantation in polycystic liver disease. Liver Transplantation 2008, 14: 680-683. PMID: 18433036, DOI: 10.1002/lt.21423.Peer-Reviewed Original ResearchConceptsPolycystic liver diseaseDonor liver transplantationLiver transplantationLiver diseaseLiver functionEnd-Stage Liver Disease (MELD) systemDeceased donor liver transplantDonor liver transplantLiver transplantCaval resectionPoor qualityMassive hepatomegalyPatient survivalLiving donationPatientsHepatomegalyTransplantationHepatectomyDiseaseIdeal optionLDLTResectionComplicationsTransplantGraft
2007
Coccidioidomycosis masked by symptoms of end‐stage liver disease in transplant candidates
Sachdev MS, Blair JE, Mulligan DC, Kusne S. Coccidioidomycosis masked by symptoms of end‐stage liver disease in transplant candidates. Transplant Infectious Disease 2007, 9: 153-155. PMID: 17462003, DOI: 10.1111/j.1399-3062.2007.00215.x.Peer-Reviewed Original Research
2006
Reduced Priority MELD Score for Hepatocellular Carcinoma Does Not Adversely Impact Candidate Survival Awaiting Liver Transplantation
Sharma P, Harper AM, Hernandez JL, Heffron T, Mulligan DC, Wiesner RH, Balan V. Reduced Priority MELD Score for Hepatocellular Carcinoma Does Not Adversely Impact Candidate Survival Awaiting Liver Transplantation. American Journal Of Transplantation 2006, 6: 1957-1962. PMID: 16771808, DOI: 10.1111/j.1600-6143.2006.01411.x.Peer-Reviewed Original ResearchConceptsDeceased donor liver transplantationHepatocellular carcinomaHCC candidatesCandidate survivalLiver transplantationMELD scoreStage T1Waiting listEnd-stage liver diseaseDonor liver transplantationT2 hepatocellular carcinomaOrgan allocation policyUNOS databaseLiver transplantLiver diseasePatient survivalUnited NetworkHCC patientsIncidence rateOrgan SharingSurvivalTransplantationCarcinomaDropout rateTime periodLiver Transplantation in the MELD Era: A Single-Center Experience
Sachdev M, Hernandez JL, Sharma P, Douglas DD, Byrne T, Harrison ME, Mulligan D, Moss A, Reddy K, Vargas HE, Rakela J, Balan V. Liver Transplantation in the MELD Era: A Single-Center Experience. Digestive Diseases And Sciences 2006, 51: 1070-1078. PMID: 16865573, DOI: 10.1007/s10620-006-8011-1.Peer-Reviewed Original ResearchMeSH KeywordsArizonaCarcinoma, HepatocellularFemaleHepatitis CHumansLiver DiseasesLiver NeoplasmsLiver TransplantationMaleMedical RecordsMiddle AgedOutcome Assessment, Health CareResource AllocationRetrospective StudiesRisk AssessmentSeverity of Illness IndexSurvival AnalysisTissue and Organ ProcurementWaiting ListsConceptsDeceased donor liver transplantationLiver transplantationTransplantation ratesEndstage Liver Disease (MELD) scoreImpact of MELDDonor liver transplantationLiver Disease scoreUnderlying liver diseaseSingle-center experienceHepatocellular carcinoma patientsHepatitis C virusNew allocation policyHCC candidatesMELD implementationNew MELDTimely transplantClinical deteriorationMELD eraCarcinoma patientsLiver diseaseHepatitis C virus groupC virusHCC patientsMayo ClinicDropout rate
2004
New preservation solutions for use in liver transplantation
Mulligan D, Reddy K, Moss A. New preservation solutions for use in liver transplantation. Current Opinion In Organ Transplantation 2004, 9: 159-162. DOI: 10.1097/01.mot.0000127629.78517.06.Peer-Reviewed Original ResearchNew preservation solutionLiver transplantationPreservation solutionDonor liversClinical studiesEnd-stage liver diseasePartial liver graftsMainstay of treatmentOrgan preservation solutionsLiver graftsReperfusion injuryLiver diseaseMarginal organsWaiting listWisconsin solutionTransplantationExperimental modelContinuous perfusionIdentification of pathwaysLiverRecent findingsIschemiaNovel advancesCelsiorGraftHepatopulmonary syndrome after living donor liver transplantation and deceased donor liver transplantation: A single‐center experience
Carey EJ, Douglas DD, Balan V, Vargas HE, Byrne TJ, Moss AA, Mulligan DC. Hepatopulmonary syndrome after living donor liver transplantation and deceased donor liver transplantation: A single‐center experience. Liver Transplantation 2004, 10: 529-533. PMID: 15048796, DOI: 10.1002/lt.20127.Peer-Reviewed Original ResearchConceptsDeceased donor liver transplantationDonor liver transplantationHepatopulmonary syndromeLiver transplantationShunt fractionEnd-stage liver diseaseLiver transplant recipientsSingle-center experienceNormal pulmonary functionMean shunt fractionTransplant recipientsMean PaO2Pulmonary functionLiver diseaseSingle centerSupplemental oxygenNatural courseTransplantationHepatic regenerationSmall seriesPatientsLDLTPaO2SyndromeComplicationsHepatitis C Virus Recurrence in Living Donor Liver Transplant Recipients
Rodriguez-Luna H, Vargas HE, Sharma P, Ortiz J, De Petris G, Balan V, Byrne T, Moss A, Mulligan D, Rakela J, Douglas DD. Hepatitis C Virus Recurrence in Living Donor Liver Transplant Recipients. Digestive Diseases And Sciences 2004, 49: 38-41. PMID: 14992432, DOI: 10.1023/b:ddas.0000011599.78222.9e.Peer-Reviewed Original ResearchConceptsDeceased donor transplantationHepatitis C virusLiver transplantationLDLT groupDonor liver transplant recipientsHepatitis C virus recurrenceEnd-stage liver diseaseHCV RNA titersLiver transplant populationLiver transplant recipientsIncidence of rejectionHistological recurrenceChronic hepatitisTransplant recipientsVirus recurrenceDonor transplantationTransplant populationHCV PCRLiver biopsyLiver diseaseAggressive recurrenceSingle pathologistC virusRNA titersInstitutional protocolLiver transplantation for hepatocellular carcinoma: The MELD impact
Sharma P, Balan V, Hernandez JL, Harper AM, Edwards EB, Rodriguez‐Luna H, Byrne T, Vargas HE, Mulligan D, Rakela J, Wiesner RH. Liver transplantation for hepatocellular carcinoma: The MELD impact. Liver Transplantation 2004, 10: 36-41. PMID: 14755775, DOI: 10.1002/lt.20012.Peer-Reviewed Original ResearchConceptsDeceased donor liver transplantationNew allocation policyHCC candidatesPerson yearsIncidence rateHepatocellular carcinomaLiver transplantationUNOS databaseEnd-stage liver diseaseT2 hepatocellular carcinomaDonor liver transplantationDropout rateDate of implementationHepatic decompensationNew MELDClinical deteriorationMELD scoreLiver diseaseStage T1United NetworkOrgan SharingWaiting listSurvivalTransplantationCarcinoma
2003
Early results of targeted prophylaxis for coccidioidomycosis in patients undergoing orthotopic liver transplantation within an endemic area
Blair JE, Douglas DD, Mulligan DC. Early results of targeted prophylaxis for coccidioidomycosis in patients undergoing orthotopic liver transplantation within an endemic area. Transplant Infectious Disease 2003, 5: 3-8. PMID: 12791068, DOI: 10.1034/j.1399-3062.2003.00005.x.Peer-Reviewed Original ResearchConceptsOrthotopic liver transplantationLiver transplantationPositive serologic resultsCoccidioidal infectionSerologic resultsEndemic areasEnd-stage liver diseaseReactivation of coccidioidomycosisRisk of coccidioidomycosisLiver transplant candidatesEndemic fungal infectionProphylactic fluconazoleTransplant recipientsUniversal prophylaxisDisseminated diseaseTransplant candidatesImmunocompromised hostLiver diseaseRecurrent infectionsClose surveillancePositive historyPatientsProphylaxisTransplantationHigh mortalityTacrolimus as a liver flush solution to ameliorate the effects of ischemia/reperfusion injury following liver transplantation
St. Peter SD, Post DJ, Rodriguez‐Davalos M, Douglas DD, Moss AA, Mulligan DC. Tacrolimus as a liver flush solution to ameliorate the effects of ischemia/reperfusion injury following liver transplantation. Liver Transplantation 2003, 9: 144-149. PMID: 12548508, DOI: 10.1053/jlts.2003.50018.Peer-Reviewed Original ResearchConceptsIschemia/reperfusion injuryTacrolimus treatmentReperfusion injuryFlush solutionGroup 2Group 1Partial thromboplastin time valuesBaseline aspartate aminotransferaseEarly graft functionOrthotopic liver transplantProspective randomized fashionTotal ischemia timeSerum laboratory valuesSuperior early graft functionGraft functionLiver transplantLiver transplantationHepatic allograftsHepatocellular injuryLiver injuryPlacebo treatmentLiver diseasePlasma-Lyte AHepatocellular damageIschemia time